Research identifies DSG2+ cancer stem cells co-located with FAP+ myofibroblasts in the tumor boundary, influencing immunotherapy efficacy in non-small cell lung cancer. This discovery could inform future treatment strategies for this prevalent cancer type.
dsg2 cancer stem cells co located with fap myofibroblasts in the tumor boundary that determines the efficacy of immunotherapy in non small cell lung cancer
Original title: “DSG2+ Cancer Stem Cells Co-Located With FAP+ Myofibroblasts in the Tumor Boundary That Determines the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer.”